Sagimet Biosciences Inc. Temporary Equity, Liquidation Preference
Sagimet Biosciences Inc. (SGMT) had Temporary Equity, Liquidation Preference of $232.96 million as of 2023-06-30, per its 10-Q filed 2023-08-21.
Discontinued › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2024-03-25
- 2023-06-30: Temporary Equity, Liquidation Preference $232.96M.
- 2022-12-31: Temporary Equity, Liquidation Preference $232.96M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2023-06-30 | $232.96M 10-Q · filed 2023-08-21 |
| 2022-12-31 | $232.96M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |